<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956838</url>
  </required_header>
  <id_info>
    <org_study_id>NL44428.068.13/METC 13-2-025</org_study_id>
    <nct_id>NCT01956838</nct_id>
  </id_info>
  <brief_title>The Effect of Bitter, Umami and Sweet Tastants on Food Intake</brief_title>
  <official_title>The Effect of Bitter, Umami and Sweet Tastants on Food Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: The appearance of tastants in the small intestine can result in the activation of
      a negative feedback mechanism from different parts of the intestine to the stomach, the small
      intestine and to the central nervous system. These processes inhibit food processing,
      appetite sensations and food intake, and furthermore they increase feelings of satiety and
      satiation. We will investigate the effects of intraduodenal infusion of quinine 75mg
      (bitter), rebaudioside A 540mg (sweet), monosodium glutamate 2g (umami), a combination of
      these tastants (quinine, rebaudioside A, monosodium glutamate) and placebo (5 test days in
      total) on ad libitum food intake, satiation and in vivo release of the gut satiety peptides
      CCK and GLP-1.

      Study design: To assess the effect of intraduodenal infusion of single ingredients and a
      combination of tastants (bitter, umami and sweet) on ad libitum food intake.

      Secondary Objective(s):

        1. To investigate the effect of intraduodenal delivery of a combination of tastants on
           satiation.

        2. To assess the effect of intraduodenal delivery of a combination of tastants on
           gastrointestinal hormone release.

        3. To assess the effects of the tastants quinine, rebaudioside A and monosodium glutamate
           on the parameters as mentioned under the primary objective, and under secondary
           objectives 1 and 2.

        4. To compare the effects, as mentioned under the primary objective, and under secondary
           objectives 1 and 2, of the combination of tastants to those of the three single tastants
           quinine, rebaudioside A and monosodium glutamate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ad libitum meal intake</measure>
    <time_frame>5 weeks</time_frame>
    <description>Difference in ad libitum meal intake (as measured during ad libitum pasta meal). At end of the testday</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satiation</measure>
    <time_frame>5 weeks</time_frame>
    <description>Difference in satiation (as measured by VAS) per time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut hormones</measure>
    <time_frame>5 weeks</time_frame>
    <description>Measurements in plasma levels of the gut hormones CCK, GLP-1, insulin and glucose</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Umami</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intraduodenal infusion of umami</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sweet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intraduodenal infusion of sweet tastant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bitter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intraduodenal infusion of bitter tastant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intraduodenal infusion of a combination of tastants (umami, bitter and sweet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intraduodenal infusion of placebo (tap water)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>umami</intervention_name>
    <description>intraduodenal infusion of umami tastant</description>
    <arm_group_label>Umami</arm_group_label>
    <arm_group_label>combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>bitter</intervention_name>
    <description>intraduodenal infusion of bitter tastant</description>
    <arm_group_label>bitter</arm_group_label>
    <arm_group_label>combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>sweet</intervention_name>
    <description>intraduodenal infusion of sweet tastant</description>
    <arm_group_label>sweet</arm_group_label>
    <arm_group_label>combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Based on medical history and previous examination, no gastrointestinal complaints can
             be defined.

          -  Age between 18 and 65 years. This study will include healthy adult subjects (male and
             female). Women must be taking contraceptives.

          -  BMI between 18 and 25 kg/m2)

          -  Weight stable over at least the last 6 months

        Exclusion Criteria:

          -  History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic,
             hematological/immunologic, HEENT (head, ears, eyes, nose, throat),
             dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine,
             neurological/psychiatric diseases, allergy, major surgery and/or laboratory
             assessments which might limit participation in or completion of the study protocol.
             The severity of the disease (major interference with the execution of the experiment
             or potential influence on the study outcomes) will be decided by the principal
             investigator.

          -  Use of medication, including vitamin supplementation, except oral contraceptives,
             within 14 days prior to testing

          -  Administration of investigational drugs or participation in any scientific
             intervention study which may interfere with this study (to be decided by the principle
             investigator), in the 180 days prior to the study

          -  Major abdominal surgery interfering with gastrointestinal function (uncomplicated
             appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon
             judgement of the principle investigator)

          -  Dieting (medically prescribed, vegetarian, diabetic, macrobiological, biological
             dynamic)

          -  Pregnancy, lactation

          -  Excessive alcohol consumption (&gt;20 alcoholic consumptions per week)

          -  Smoking

          -  Blood donation within 3 months before the study period

          -  Self-admitted HIV-positive state

          -  Weight &lt;60kg

          -  Non-tasters of sweet, bitter or umami

          -  Evidence of MSG-hypersensitivity or Chinese restaurant syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Masclee, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2013</study_first_submitted>
  <study_first_submitted_qc>September 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>October 13, 2014</last_update_submitted>
  <last_update_submitted_qc>October 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>food intake</keyword>
  <keyword>tastants</keyword>
  <keyword>obesity</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

